Maze Therapeutics (NASDAQ:MAZE) Given New $37.00 Price Target at BTIG Research

Key Points

• BTIG Research has raised the price target for Maze Therapeutics from $30 to $37, indicating a potential upside of 49.19% based on the company's previous close.
• The stock has received multiple positive ratings, including a consensus rating of "Buy" from several analysts, with two analysts giving a Strong Buy rating.
• Initially, the company reported earnings of ($0.77) EPS, which was better than the consensus estimate of ($0.79), showcasing an improvement in financial performance.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) had its price target lifted by stock analysts at BTIG Research from $30.00 to $37.00 in a report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. BTIG Research's price objective suggests a potential upside of 49.19% from the company's previous close.

A number of other equities research analysts have also issued reports on the stock. HC Wainwright assumed coverage on shares of Maze Therapeutics in a report on Wednesday, July 23rd. They set a "buy" rating and a $34.00 price objective for the company. Wedbush assumed coverage on shares of Maze Therapeutics in a report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price objective for the company. Finally, Wall Street Zen raised shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Two analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $30.17.

Maze Therapeutics Price Performance

Maze Therapeutics stock opened at $24.80 on Friday. The firm has a 50 day moving average of $15.04 and a 200 day moving average of $12.19. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $25.50.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Institutional Trading of Maze Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. TRV GP IV LLC purchased a new position in shares of Maze Therapeutics during the first quarter valued at $66,874,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Maze Therapeutics during the first quarter valued at $45,460,000. ARCH Venture Management LLC purchased a new position in shares of Maze Therapeutics during the first quarter valued at $45,362,000. Matrix Capital Management Company LP purchased a new position in shares of Maze Therapeutics during the first quarter valued at $27,373,000. Finally, Alphabet Inc. purchased a new position in shares of Maze Therapeutics during the first quarter valued at $26,561,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.